ARNA stock news

SAN DIEGO, Nov. 6, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) presented new data evaluating the human mass balance, metabolic disposition, and pharmacokinetics (PK) of etrasimod in healthy adult male volunteers. Etrasimod is an investigational next-generation,… Read more
SAN DIEGO, Oct. 31, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its third quarter 2019 financial results and provide a corporate update on Thursday, November 7, 2019, after the close of the U.S. financial markets. The Company will host a conference call… Read more
- ADVISE clinical trial initiated and enrollment progressing - Evaluating patients with the clinical diagnosis of moderate-to-severe atopic dermatitis - Significant unmet need for an oral therapy in atopic dermatitis SAN DIEGO, Oct. 28, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc…. Read more
Arena Pharmaceuticals (ARNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Read more
Arena Pharmaceuticals (ARNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). Read more
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 1) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) Argenx SE – ADR (NASDAQ: ARGX ) ArQule, Inc. (NASDAQ: ARQL ) Axsome Therapeutics Inc (NASDAQ: AXSM ) (the company's stock has been added to Russell 3000 and Russell 2000 Indexes) Coherus Biosciences Inc (NASDAQ: CHRS )(announced that it has produced over 400,000 Udenyca pre-filled syringes to date) Fate Therapeutics Inc (NASDAQ: FATE ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) MeiraGTx Holdings PLC (NASDAQ: MGTX ) Misonix, Inc. (NASDAQ: MSON ) (the company's stock has been added to Russell 3000 and Russell 2000 Indexes) Morphic Holding Inc (NASDAQ: MORF )(IPOed June 27) Odonate Therapeutics Inc (NASDAQ: ODT ) Ra Pharmaceuticals Inc (NASDAQ: RARX ) ResMed Inc. (NYSE: RMD ) Tricida Inc (NASDAQ: TCDA ) Vapotherm Inc (NYSE: VAPO ) Zai Lab Ltd (NASDAQ: ZLAB ) Down In The Dumps (Biotech stocks hitting 52-week lows on July 1) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Artelo Biosciences Inc (NASDAQ: ARTL ) CELLECT … Read more
Arena Pharmaceuticals (ARNA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. Read more
Jim Cramer weighs in on Arena Pharmaceuticals, DaVita, Merck, Abbott Laboratories, IAC Interactive, Yext and more….ARNA Read more
Jim Cramer takes calls and delivers answers to caller stock picks in the latest lightning round. Read more
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 15) Applied Therapeutics Inc (NASDAQ: APLT ) (debuted on Tuesday) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) Avedro Inc (NASDAQ: AVDR ) Axsome Therapeutics Inc (NASDAQ: AXSM ) MeiraGTx Holdings PLC (NASDAQ: MGTX ) Shockwave Medical Inc (NASDAQ: SWAV ) Silk Road Medical Inc (NASDAQ: SILK ) Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE ) Down In The Dumps (Biotech stocks hitting 52-week lows on May 15) Amneal Pharmaceuticals Inc (NYSE: AMRX ) Auris Medical Holding Ltd (NASDAQ: EARS ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI )(reacted to its third-quarter results) ENDRA Life Sciences Inc (NASDAQ: NDRA )(reacted to its first-quarter results) ImmunoGen, Inc. (NASDAQ: IMGN )(FDA required a new Phase 3 study to be conducted for its ovarian cancer drug) Nuvectra Corp (NASDAQ: NVTR ) Outlook Therapeutics Inc (NASDAQ: OTLK )(reacted to its second quarter results) Teva Pharmaceutical Industries Ltd (NYSE: TEVA ) United Therapeutics Corporation (NASDAQ: UTHR ) Stock In Focus Roche Gets FDA Nod For Leukemia Drug, Reports Positive Results For Solid Tumor Drug Roche Holdings AG Basel ADR (OTC: RHHBY ) said the FDA approved Venclexta in combination with Gazyva for treating people with previously untreated chronic lymphocytic leukemia, or CLL, or small lymphocytic lymphoma, or SLL. Read more
Arena Pharmaceuticals (ARNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). Read more
ARNA earnings call for the period ending March 31, 2019. Read more
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Q1 2019 Results Earnings Conference Call May 08, 2019, 04:30 PM ET Company Participants Kevin Lind - Chief Financial O Read more
Arena Pharmaceuticals (ARNA) reports loss in the first quarter of 2019 on an adjusted basis. Revenues of $801.1 million include upfront payment of $800 million from United Therapeutics. Read more
Shares of Arena Pharmaceuticals Inc. declined in Wednesday's extended session after the drug company posted quarterly results that fell short of… Read more

Proudly made at

ROCKIT